alexa Lovastatin for adult patients with dengue: protocol for a randomised controlled trial.
Bioinformatics & Systems Biology

Bioinformatics & Systems Biology

Journal of Computer Science & Systems Biology

Author(s): Whitehorn J, Van Vinh Chau N, Truong NT, Tai LT, Van Hao N,

Abstract Share this page

Abstract BACKGROUND: Dengue is the most important vector-borne viral infection of man, with approximately 2 billion people living in areas at risk. Infection results in a range of manifestations from asymptomatic infection through to life-threatening shock and haemorrhage. One of the hallmarks of severe dengue is vascular endothelial disruption. There is currently no specific therapy and clinical management is limited to supportive care. Statins are a class of drug initially developed for lipid lowering. There has been considerable recent interest in their effects beyond lipid lowering. These include anti-inflammatory effects at the endothelium. In addition, it is possible that lovastatin may have an anti-viral effect against dengue. Observational data suggest that the use of statins may improve outcomes for such conditions as sepsis and pneumonia. This paper describes the protocol for a randomised controlled trial investigating a short course of lovastatin therapy in adult patients with dengue. METHODS/DESIGN: A randomised, double-blind, placebo-controlled trial will investigate the effects of lovastatin therapy in the treatment of dengue. The trial will be conducted in two phases with an escalation of dose between phases if an interim safety review is satisfactory. This is an exploratory study focusing on safety and there are no data on which to base a sample size calculation. A target sample size of 300 patients in the second phase, enrolled over two dengue seasons, was chosen based on clinical judgement and feasibility considerations. In a previous randomised trial in dengue, about 10\% and 30\% of patients experienced at least one serious adverse event or adverse event, respectively. With 300 patients, we will have 80\% power to detect an increase of 12\% (from 10\% to 22\%) or 16\% (from 30\% to 46\%) in the frequency of adverse events. Furthermore, this sample size ensures some power to explore the efficacy of statins. DISCUSSION: The development of a dengue therapeutic that can attenuate disease would be an enormous advance in global health. The favourable effects of statins on the endothelium, their good safety profile and their low cost make lovastatin an attractive therapeutic candidate. TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number ISRCTN03147572.
This article was published in Trials and referenced in Journal of Computer Science & Systems Biology

Relevant Expert PPTs

Relevant Speaker PPTs

  • Kun Yin
    Make Your Immunology Research Easy
    PPT Version | PDF Version
  • Anjana Rajput
    Conservation of superior phenotypes of teak (Tectona grandis) in central India
    PPT Version | PDF Version
  • Francesco Fontana
    Wearable artificial kidney - back to the future: A review
    PPT Version | PDF Version
  • Soha S M Mostafa
    Phycoremediation of olive mill wastewater (OMW) using cyanobacteria for sustainable bio fertilizer and biofuel production
    PPT Version | PDF Version
  • M V Raghavendra Rao
    Medical research – Scorpion as model
    PPT Version | PDF Version
  • A K Sreekala
    Floral structure in relation to pollination and breeding system of selected endemic Impatiens of Western Ghats
    PPT Version | PDF Version
  • Manche Santoshi Kumari
    Prevalence of otological disorders in diabetic patients with hearing loss
    PPT Version | PDF Version
  • Chol-Bum ‘Mike’ Kweon
    Chol-Bum-Mike-Kweon-US-Army-Research-Laboratory-USA-Unmanned-Aerial-System-(UAS)-engine-research-at-US-Army-research-laboratory
    PPT Version | PDF Version
  • Qilian Xie
    Accompanying mild hypothermia significantly improved the prognosis of septic mice than artificial mild hypothermia
    PPT Version | PDF Version
  • S. R. Gollahalli
    S-R-Gollahalli-University-of-Oklahoma-USA-An-integrative-research-program-of-bio-fuel-combustion-performance-and-emissions
    PPT Version | PDF Version
  • Saroj Velamakanni
    Multiparameter analysis using cell cycle biomarkers for breast cancer: Prognostic and predictive implications
    PPT Version | PDF Version
  • Hazel Gorham
    Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
    PPT Version | PDF Version
  • Wang Bin
    Wang-Bin-Nanjing-University-of-Aeronautics-and-Astronautics-China-Simulation-research-of-driving-schemes-for-a-dynamic-calibration-system-of-fuel-turbine-flow-meters
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Lu Jia
    Lu-Jia-Taiyuan-University-of-Science-and-Technology-China-The-research-on-technological-parameters-of-short-forming-process-of-ring-parts
    PPT Version | PDF Version

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords